AIgnostics

AIgnostics' core business involves developing AI-powered solutions that analyze complex, multimodal biomedical data, primarily for biopharmaceutical companies. Its services support various stages of the pharmaceutical pipeline, including novel target identification, translational research, clinical trials, and the development of companion diagnostics (CDx). The company's business model is centered on collaborations and providing custom services for complex image and data analysis. A key offering is its patented "Explainable AI" technology, which aims to overcome the "black-box" issue in AI by making diagnostic results verifiable through heatmaps and image overlays. In 2024, AIgnostics announced a strategic multi-year collaboration with Bayer to co-develop a novel target identification platform and computational pathology algorithms for precision oncology. The company also works with the Mayo Clinic on developing pathology foundation models.

The company has developed foundation models for pathology, such as 'RudolfV' and 'Atlas 2', trained on extensive image datasets. These models are designed to be computationally efficient and to assist in biomarker, cell, and tissue image analysis. AIgnostics provides its clients with access to its technology and proprietary multimodal patient data to accelerate drug research and development. Headquartered in Berlin, Germany, with operations in New York, the company has grown to over 120 employees. AIgnostics has successfully raised over $55 million in funding, including a $34 million Series B round in October 2024. This round was led by ATHOS, with participation from Mayo Clinic, HTGF, and existing investors like Wellington Partners and Boehringer Ingelheim Venture Fund.